Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent

AMARIN CORP PLCUK

EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.
Amarin successfully defended separate VAZKEPA patent (expires June 2033) against third-party opposition at EPO.
Legacy patent exclusivity from ANCHOR study extended via SPCs until June 2035.
Regulatory exclusivity for VAZKEPA in Europe runs until March 2031, layering with patent protections.
CEO Patrick Holt says extended runway enhances commercial and growth potential for VAZKEPA in Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.